The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
STING Pathway Expression Identifies NSCLC With an Immune-Responsive Phenotype
Open accessAbstract
Purpose Although the combination of anti-PD1/PD-L1 with platinum chemotherapy is a standard of care for NSCLC, clinical responses vary. While predictive biomarkers are validated for immunotherapy, including PD-L1 expression, tumor mutational burden, and inflamed immune microenvironment, their relevance to chemo-immunotherapy combinations is less clear. We have recently shown that activation of the STING innate immune pathway enhances immunotherapy response in SCLC. We hypothesize that STING pathway activation may predict and underlie predictive correlates of anti-tumor immunity in NSCLC. Experimental Design We analyzed transcriptomic and proteomic profiles in two NSCLC cohorts from our institution (treatment-naïve-PROSPECT; relapsed-BATTLE-2) and The Cancer Genome Atlas (total n=1320). Tumors were stratified by STING activation based on protein and/or mRNA expression of cGAS, phospho-STING, and STING-mediated-chemokines CCL5 and CXCL10. STING activation in patient tumors and in platinum-treated preclinical NSCLC models was correlated with biomarkers of immunotherapy response. Results STING activation is associated with higher levels of intrinsic DNA damage, targetable immune checkpoints, and chemokines in treatment-naïve and relapsed lung adenocarcinoma. We observed that tumors with lower STING and immune gene expression show higher frequency of STK11 mutations; however, we identified a subset of these tumors that are TP53 co-mutated and display high immune- and STING- related gene expression. Treatment with cisplatin increases STING pathway activation and PD-L1 expression in multiple NSCLC preclinical models, including adeno- and squamous cell carcinoma. Conclusions STING pathway activation in NSCLC predicts features of immunotherapy response and is enhanced by cisplatin treatment, suggesting a possible predictive biomarker, and mechanism, for improved response to chemo-immunotherapy combinations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer
Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801005 · Cited by 6,607 · cited 15×
“Clinical cohort Histology Treatment n Genomic profile STING/Immune Transcriptomic profile STING/Immune Proteomic profile PROSPECT LUSC Naïve 57 n=57 n=36 PROSPECT LUAD Naïve 152 n=152 n=120 TCGA LUSC Naïve 501 n=501 n=501 TCGA LUAD Naïve 515 n=511 n=511 BATTLE-2 LUAD Relapsed 255 n=95 J Thorac Oncol.”
InfluentialComprehensive molecular profiling of lung adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13385 · Cited by 5,732 · cited 9×
“These observations were then validated in the larger independent TCGA LUAD cohort (n=511, rho>0.6, p 0.001) (Supplemental Figure 1A).”
InfluentialIFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
Ayers, M., Lunceford, J., Nebozhyn, M., Murphy, E., Loboda, A., Kaufman, D. R., Albright, A., Cheng, J. D., Kang, S. P., Shankaran, V., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci91190 · Cited by 3,788
Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer
Paz-Ares, L., Luft, A., Vicente, D., Tafreshi, A., Gümüş, M., Mazières, J., Hermes, B., Çay Şenler, F., Csőszi, T., Fülöp, A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1810865 · Cited by 3,617 · cited 15×
“Clinical cohort Histology Treatment n Genomic profile STING/Immune Transcriptomic profile STING/Immune Proteomic profile PROSPECT LUSC Naïve 57 n=57 n=36 PROSPECT LUAD Naïve 152 n=152 n=120 TCGA LUSC Naïve 501 n=501 n=501 TCGA LUAD Naïve 515 n=511 n=511 BATTLE-2 LUAD Relapsed 255 n=95 J Thorac Oncol.”
InfluentialNivolumab plus ipilimumab in lung cancer with a high tumor mutational burden
Hellmann, M. D., Ciuleanu, T.-E., Pluzanski, A., Lee, J. S., Otterson, G. A., Audigier-Valette, C., Minenza, E., Linardou, H., Burgers, S., Salman, P., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801946 · Cited by 3,063 · cited 1×
“Analyses of clinical datasets have identified high tumor mutation burden (TMB) (2) and PD-L1 expression (3) as predictors of favorable T-cell responses, while somatic mutations (like EGFR and KRAS/STK11) are associated with lack of T-cell response (4, 5).”
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma
Skoulidis, F., Goldberg, M. E., Greenawalt, D. M., Hellmann, M. D., Awad, M. M., Gainor, J. F., Schrock, A. B., Hartmaier, R. J., Trabucco, S. E., Gay, L., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0099 · Cited by 1,641 · cited 7×
“(4, 23) demonstrated that, among KRAS mutated LUAD, tumors with STK11(LKB1) mutations are immunologically “cold” and are intrinsically resistant to anti-PD1/PD-L1 immunotherapy, and they have low expression of immune markers (including PD1, CTLA4, PD-L1, CD8) compared to other LUAD.”
InfluentialSelf-citationRizvi, H., Sanchez-Vega, F., La, K., Chatila, W., Jonsson, P., Halpenny, D., Plodkowski, A., Long, N., Sauter, J. L., Rekhtman, N., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.3384 · Cited by 1,367 · cited 2×
“While several groups have identified STK11 mutations as predictive of poor response to immunotherapy and that STK11/KRAS mutant lung adenocarcinoma have low PD-L1 expression and STING gene silencing (26, 27), our data suggest that among the STK11 mutant subgroup, there are a range of inflammatory phenotypes defined by…”
STING: infection, inflammation and cancer.
Barber, G. N. (2015) · Nature Reviews Immunology · doi:10.1038/nri3921 · Cited by 1,313 · cited 1×
“from DNA damage) are detected by Cyclic GMP-AMP synthase (cGAS) which, in turn, activates the Stimulator of Interferon Genes (STING) pathway and, subsequently, a type-I interferon (IFN) response (14).”
Ott, P. A., Bang, Y.-J., Piha-Paul, S. A., Razak, A. R. A., Bennouna, J., Soria, J.-C., Rugo, H. S., Cohen, R. B., O’Neil, B. H., Mehnert, J. M., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.2276 · Cited by 969 · cited 1×
“This score has been validated as an independent positive biomarker for clinical responses to anti-PD1 monotherapy in pan-cancer clinical trials including lung cancer; tumors with positive score can be defined as “inflamed” and this is an independent biomarker of immunotherapy response (7, 8).”
Skoulidis, F., Byers, L. A., Diao, L., Papadimitrakopoulou, V. A., Tong, P., Izzo, J., Behrens, C., Kadara, H., Parra, E. R., Canales, J. R., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1236 · Cited by 936
Self-citationSen, T., Rodriguez, B. L., Chen, L., Corte, C. M. D., Morikawa, N., Fujimoto, J., Cristea, S., Nguyen, T., Diao, L., Li, L., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1020 · Cited by 902 · cited 10×
“previous studies have shown that cisplatin treatment activates STING and PD-L1 expression in models of breast cancer (11) and SCLC (12), supporting the idea of a connection between innate and adaptive anti-cancer immunity.”
InfluentialSelf-citationCheckpoint inhibitors in metastatic EGFR-mutated non–small cell lung cancer-a meta-analysis
Lee, C. K., Man, J., Lord, S., Links, M., Gebski, V., Mok, T., & Yang, J. C.-H. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.10.007 · Cited by 839
Dunphy, G., Flannery, S. M., Almine, J. F., Connolly, D. J., Paulus, C., Jønsson, K. L., Jakobsen, M. R., Nevels, M. M., Bowie, A. G., & Unterholzner, L. (2018) · Molecular Cell · doi:10.1016/j.molcel.2018.07.034 · Cited by 648
PARP inhibition elicits STING-dependent antitumor immunity in brca1-deficient ovarian cancer
Ding, L., Kim, H.-J., Wang, Q., Kearns, M., Jiang, T., Ohlson, C. E., Li, B. B., Xie, S., Liu, J. F., Stover, E. H., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.11.054 · Cited by 572
Parkes, E. E., Walker, S. M., Taggart, L. E., McCabe, N., Knight, L. A., Wilkinson, R., McCloskey, K. D., Buckley, N. E., Savage, K. I., Salto-Tellez, M., et al. (2017) · Journal of the National Cancer Institute · doi:10.1093/jnci/djw199 · Cited by 462
CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade
Chen, L., Diao, L., Yang, Y., Yi, X., Rodriguez, B. L., Li, Y., Villalobos, P. A., Cascone, T., Liu, X., Tan, L., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1033 · Cited by 462 · cited 2×
“We then compared expression of immune related genes (22) and the frequency of mutations between these two groups.”
Self-citation
Cited by
The rediscovery of platinum-based cancer therapy
Rottenberg, S., Disler, C., & Perego, P. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-020-00308-y · Cited by 972
Gay, C. M., Stewart, C. A., Park, E. M., Diao, L., Groves, S. M., Heeke, S., Nabet, B. Y., Fujimoto, J., Solis, L. M., Lu, W., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.12.014 · Cited by 962
Self-citationHuang, M.-Y., Jiang, X.-M., Wang, B.-L., Sun, Y., & Lu, J.-J. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107694 · Cited by 136
Metadata
- Authors
- Della Corte, C. M., Sen, T., Gay, C. M., Ramkumar, K., Diao, L., Cardnell, R. J., Rodriguez, B. L., Stewart, C. A., Papadimitrakopoulou, V. A., Gibson, L., Fradette, J. J., Wang, Q., Fan, Y., Peng, D. H., Negrao, M. V., Wistuba, I. I., Fujimoto, J., Solis Soto, L. M., Behrens, C., Skoulidis, F., Heymach, J. V., Wang, J., Gibbons, D. L., & Byers, L. A.
- Venue
- Journal of Thoracic Oncology
- Publisher
- Elsevier BV
- Published
- 2020-05
- Volume
- 15
- Issue
- 5
- Pages
- 777-791
- ISSN
- 1556-0864 (ISSN-L)
- OpenAlex
- W3006378317
- Cited by
- 180
- References
- 18
- FWCI
- 9.94
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.